FRANKFURT (Reuters) - Bayer struck a collaboration deal with Roche’s Foundation Medicine Inc. to develop test kits for genetic sequencing of tumor cells to identify cancer patients that benefit from Bayer’s Vitrakvi drug. Vitrakvi, which Bayer acquired from Eli Lilly’s Loxo Oncology, has been shown to shrink tumors in about 1 percent of patients across a range 24 different cancer types. Identifying those patients requires advanced genetic diagnostic tools. Reporting by Ludwig Burger; Editing by Thomas Seythal
Bayer has agreed a deal with Foundation Medicine to develop test kits which can be used to identify patients for its Vitrakvi cancer therapy. The company said the kit will help doctors and researchers better understand how their drugs work in different types of cancer.